BackgroundThe high‐fat Western diet is postulated to be associated with the onset and progression of Alzheimer's disease (AD). However, the role of high‐fat‐diet consumption in AD pathology is unknown. This study was undertaken to examine the role of high‐fat‐diet intake in AD.Methods and Results5XFAD mice, a useful mouse model of AD, and control wild‐type mice were fed (1) high‐fat diet or (2) control diet for 10 weeks. The effects on cerebral AD pathology, cognitive function, and metabolic parameters were compared between each group of mice. High‐fat diet significantly enhanced cerebrovascular β‐amyloid (Aβ) deposition (P<0.05) and impaired cognitive function (P<0.05) in 5XFAD mice, but not in wild‐type mice. High‐fat diet enhanced hippocampal oxidative stress (P<0.05) and NADPH oxidase subunits, gp91phox (P<0.01) and p22phox (P<0.01) in 5XFAD mice, but not in wild‐type mice. Furthermore, high‐fat diet reduced cerebral occludin (P<0.05) in 5XFAD mice, but not in wild‐type mice. Thus, 5XFAD mice exhibited greater susceptibility to high‐fat diet than wild‐type mice regarding cerebrovascular injury and cognitive impairment. On the other hand, 5XFAD mice fed high‐fat diet exhibited much less increase in body weight, white adipose tissue weight, and adipocyte size than their wild‐type counterparts. High‐fat diet significantly impaired glucose tolerance in wild‐type mice but not in 5XFAD mice. Thus, 5XFAD mice had much less susceptibility to high‐fat‐diet‐induced metabolic disorders than wild‐type mice.ConclusionsHigh‐fat diet, independently of metabolic disorders, significantly promotes the progression of AD‐like pathology through enhancement of cerebral amyloid angiopathy and oxidative stress.

BackgroundThe significance of brain angiotensin II in Alzheimer disease (AD) is unclear.Methods and ResultsTo examine the role of brain angiotensin II in AD, intracerebroventricular angiotensin II infusion was performed on 5XFAD mice, a mouse model of AD, and wild‐type mice, and the detrimental effects of brain angiotensin II was compared between the 2 strains of mice. Intracerebroventricular angiotensin II infusion significantly impaired cognitive function in 5XFAD mice but not in wild‐type mice. This vulnerability of 5XFAD mice to brain angiotensin II was associated with enhancement of hippocampal inflammation and oxidative stress and with increased cerebrovascular amyloid β deposition. We also compared the effect of brain angiotensin II on the heart and skeletal muscle between the 2 strains because AD is associated with heart failure and sarcopenia. We found that cardiac compensatory response of 5XFAD mice to brain angiotensin II–induced hypertension was less than that of wild‐type mice. Brain angiotensin II caused skeletal muscle atrophy and injury in 5XFAD mice more than in wild‐type mice.ConclusionsBrain angiotensin II seems to be involved in cognitive impairment and brain injury in AD, which is associated with oxidative stress, inflammation, and cerebral amyloid angiopathy. Further, brain angiotensin II may participate in cardiac disease and sarcopenia observed in AD.

BackgroundHigh salt intake in patients with chronic kidney disease (CKD) may cause high blood pressure and increased albuminuria. Although, the estimation of salt intake is essential, there are no easy methods to estimate real salt intake.MethodsSalt intake was assessed by determining urinary sodium excretion from the collected urine samples. Estimation of salt intake by spot urine was calculated by Tanaka’s formula. The correlation between estimated and measured sodium excretion was evaluated by Pearson´s correlation coefficients. Performance of equation was estimated by median bias, interquartile range (IQR), proportion of estimates within 30% deviation of measured sodium excretion (P30) and root mean square error (RMSE).The sensitivity and specificity of estimated against measured sodium excretion were separately assessed by receiver-operating characteristic (ROC) curves.ResultsA total of 334 urine samples from 96 patients were examined. Mean age was 58 ± 16 years, and estimated glomerular filtration rate (eGFR) was 53 ± 27 mL/min. Among these patients, 35 had CKD stage 1 or 2, 39 had stage 3, and 22 had stage 4 or 5. Estimated sodium excretion significantly correlated with measured sodium excretion (R = 0.52, P < 0.01). There was apparent correlation in patients with eGFR <30 mL/min (R = 0.60, P < 0.01). Moreover, IQR was lower and P30 was higher in patients with eGFR < 30 mL/min. Estimated sodium excretion had high accuracy to predict measured sodium excretion, especially when the cut-off point was >170 mEq/day (AUC 0.835).ConclusionsThe present study demonstrated that spot urine can be used to estimate sodium excretion, especially in patients with low eGFR.

Background:The potential of anti-aging effect of DPP-4 inhibitors is unknown. This study was performed to determine whether linagliptin, a DPP-4 inhibitor, could protect against premature aging in klotho−/− mice. Methods:Klotho−/− mice exhibit multiple phenotypes resembling human premature aging, including extremely shortened life span, cognitive impairment, hippocampal neurodegeneration, hair loss, muscle atrophy, hypoglycemia, etc. To investigate the effect of linagliptin on these aging-related phenotypes, male klotho−/− mice were divided into two groups: (1) control group fed the standard diet, and (2) linagliptin group fed the standard diet containing linagliptin. Treatment with linagliptin was performed for 4 weeks. The effect of linagliptin on the above mentioned aging-related phenotypes was examined.Results: Body weight of klotho−/− mice was greater in linagliptin group than in control group (11.1 ± 0.3 vs 9.9 ± 0.3 g; P < 0.01), which was associated with greater gastrocnemius muscle weight (P < 0.01) and greater kidney weight (P < 0.05) in linagliptin group. Thus, linagliptin significantly prevented body weight loss in klotho−/− mice. Survival rate of klotho−/− mice was greater in linagliptin group (93%) compared to control group (67%), although the difference did not reach statistical significance (P = 0.08). None of linagliptin-treated klotho−/− mice had alopecia during the treatment (P < 0.05 vs control klotho−/− mice). Latency of klotho−/− mice in passive avoidance test was larger in linagliptin group than in control group (P < 0.05), indicating the amelioration of cognitive impairment by linagliptin. Cerebral blood flow of klotho−/− mice was larger in linagliptin group than in control group (P < 0.01), being associated with greater cerebral phospho-eNOS levels (P < 0.05) in linagliptin group. Neuronal cell number in hippocampal CA1 region was greater in linagliptin group than in control group (P < 0.05). Linagliptin group had greater cerebral phospho-Akt (P < 0.05) and phospho-CREB (P < 0.05) than control group. Thus, linagliptin ameliorated brain aging in klotho−/− mice. The degree of hypoglycemia in klotho−/− mice was less in linagliptin group than in control group, as estimated by the findings of OGTT. Conclusions:Out work provided the evidence that DPP-4 inhibition with linagliptin slowed the progression of premature aging in klotho−/− mice, and provided a novel insight into the potential role of DPP-4 in the mechanism of premature aging.